Jean-Paul Kress
Chief Executive Officer @ Vor Biopharma
Boston, United States
Jean-Paul Kress is a seed investor at Vor Biopharma in Boston focused on Medical and Biotechnology. Jean-Paul Kress is based out of Paris, Île-de-France and is the Chief Executive Officer and Chairman of the Board of Vor Biopharma and Independent Director of Sanofi. Jean-Paul previously worked at MorphoSys as a CEO. Jean-Paul Kress attended the Université de Paris.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Jean-Paul Kress invests in
Stages Jean-Paul Kress invests in
Countries Jean-Paul Kress invests in
Investment Focus
Industry
- Medical 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
LinKinVax
|
LinKinVax operates as a clinical-stage biotechnology company. LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI). | $5M / Seed / Feb 10, 2022 |
About Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer. It is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells. Cell surface-targeted immunotherapies, such as bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) Tcells, generally target both cancer and normal cells, causing substantial toxicities and limiting their potential. The company is taking a fundamentally novel approach to targeting cancer selectively by developing hematopoietic stem cells (HSCs) that have been engineered to be protected from specifically targeted immunotherapies. These HSCs are designed to generate healthy, functional cells that are also protected from depletion by cancer-targeted therapies.
Vor Biopharma Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jean-Paul Kress
Chief Executive Officer
|
|||
Amy Mendel
Chief Legal Officer
|
|||
Bill Lundberg
Independent Director
|
|||
Christopher Slapak
Chief Medical Officer
|
|||
John King
Chief Commercial Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Jean-Paul Kress invest in?
Jean-Paul Kress invests primarily in Medical and Biotechnology startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Jean-Paul Kress last invest?
The most recent investment recorded for Jean-Paul Kress closed in Feb 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
